Skip to content
Profiles

NMD Pharma

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases. NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle.

Their focus is on myasthenia gravis, spinal muscular atrophy, CMT, and sarcopenia. NMD’s Phase 2 SYNAPSE clinical trail for CMT launched in November 2024 with lead candidate NMD670 and is open to patients with Type 1 and Type 2 CMT.